サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1727076

精密医療向けAIの世界市場 - 市場考察、競合情勢、市場予測（2032年）

Artificial Intelligence (AI) in Precision Medicine - Market Insights, Competitive Landscape, and Market Forecast - 2032

出版日
発行
DelveInsight
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.87円
精密医療向けAIの世界市場 - 市場考察、競合情勢、市場予測（2032年）
出版日: 2025年04月01日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の精密医療向けAIの市場規模は、2024年に10億3,691万米ドルであり、2032年までに102億4,452万米ドルに達すると予測され、2025年～2032年の予測期間にCAGRで33.18%の成長が見込まれます。市場は、慢性疾患や遺伝性疾患の世界的な有病率の上昇によって個別化治療ソリューションの需要が増幅し、大幅な成長を示しています。この勢いは、複雑な生物学的データを分析するAIの能力を活用した精密診断と個別化治療に対するニーズの高まりによってさらに後押しされています。AI搭載プラットフォームの技術的進歩と革新的な製品開発が、精密介入の精度とスピードを高めています。さらに、業界の主要企業による戦略的な製品上市と並行して研究開発活動が活発化していることも、市場の拡大を加速させています。これらの集約的な要因が、2025年～2032年の予測期間に精密医療向けAI市場の成長を大きく促進する見込みです。

精密医療向けAIの市場力学

2023年のGLOBOCANのデータによると、2022年に約2,000万人人の新たながん患者が報告されており、この数は世界中で2050年までに3,500万人に増加すると予測されています。

2024年の世界保健機関（WHO）のデータによると、WHO Eastern Mediterranean Regionでは、2022年に78万8,000を超えるがん診断が記録されました。この数字は、2045年までに約157万に倍増すると予測されています。

2024年のBreast Cancer Research Foundationのデータによると、2022年に世界中で約230万人の女性が乳がんと診断されました。また、2024年のWorld Cancer Research Fundのデータによると、2022年に世界中で約248万675件の肺がんと192万6,425件の大腸がんが報告されています。

世界のがんの負荷の増加は、精密医療向けAI市場を大きく牽引しています。がん治療が複雑化するにつれて、早期発見、正確な診断、個別化治療戦略をサポートできる先進のツールへのニーズが高まっています。AIを搭載した精密医療ソリューションは、特に腫瘍において、膨大なデータセットを分析し、パターンを明らかにし、個別化治療を導く能力で勢いを増しています。

British Heart Foundation（2024年）は、2024年に世界中で約6億4,000万人が心臓・循環器系疾患に罹患し、毎年約6,700万人が新たに診断を受けていると報告しています。

さらに、International Diabetes Federation（2023年）は、2021年に20歳～79歳の成人5億3,700万人が糖尿病を患っていると述べています。この数は2030年までに6億4,300万人、2045年までに7億8,300万人に達すると予測されます。

さらにWHOのデータによると、2023年の時点で、約3億400万人がB型肝炎やC型肝炎などのウイルス感染症に罹患しています。同年、推定3,990万人がHIVを患い、うち140万人が子ども、3,860万人が成人でした。

世界的な慢性疾患や感染症の負荷の増大は、精密医療向けAI市場を大きく押し上げています。心血管疾患、糖尿病、慢性ウイルス感染症などの治療が増加の一途をたどる中、より的を絞った効率的かつ予防的な治療アプローチの必要性が高まっています。AI技術は、早期診断、個別化治療計画、リアルタイムの患者モニタリングを可能にすることで、重要な役割を果たしています。このようなデータ主導の個別化医療へのシフトは、世界中の医療制度でAIを統合した精密医療ソリューションへの需要を促進しています。

個別化医療と精密診断に対する需要の高まりは、精密医療向けAI市場の拡大を促進する上で重要な役割を果たしています。 Personalized Medicine Coalition（2024年）のデータによると、米国FDAは2023年に希少疾患患者向けに16の新しい個別化治療を承認し、2022年のわずか6の承認から増加しました。このうち7つは抗がん剤で、3つはその他の疾患や症状を対象としており、このことは個別化治療開発の機運が高まっていることを反映しています。

当レポートでは、世界の精密医療向けAI市場について調査分析し、市場規模と予測、過去3年の製品/技術開発、市場の主要企業、利用可能な機会などの情報を提供しています。

目次

第1章 精密医療向けAI市場レポートのイントロダクション

第2章 精密医療向けAI市場のエグゼクティブサマリー

  • 市場の概要

第3章 競合情勢

第4章 規制分析

第5章 精密医療向けAI市場の主な要因の分析

  • 精密医療向けAI市場の促進要因
  • 精密医療向けAI市場の抑制要因と課題
  • 精密医療向けAI市場の機会

第6章 精密医療向けAI市場のポーターのファイブフォース分析

第7章 精密医療向けAI市場の評価

  • 製品別
    • ハードウェア/ソフトウェア
    • サービス
  • 技術別
    • 深層学習
    • 自然言語処理
    • 機械学習
  • 用途別
    • 創薬、医薬品開発
    • 疾患診断
  • 治療領域別
    • 腫瘍
    • 心臓
    • 神経
    • 感染症
    • 免疫
    • その他
  • 地域
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 精密医療向けAI市場の企業と製品のプロファイル

  • TEMPUS
  • GE HealthCare
  • Qure.ai
  • Envisionit Deep AI（Pty）Ltd.
  • Avicenna.AI
  • Aignostics, Inc.
  • Proscia Inc.
  • Ultivue, Inc.
  • Prenosis, Inc.
  • IBEX
  • Cleerly, Inc.
  • Paige AI, Inc.
  • Densitas（R）Inc.Co.
  • Photocure ASACo.
  • iCAD, Inc.
  • Eko Health, Inc.
  • Owkin, Inc.
  • Massive Bio
  • Deep Bio Inc., Inc.
  • Atomwise Inc.

第9章 KOLの見解

第10章 DelveInsightについて

第11章 免責事項、お問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Artificial Intelligence (AI) in Precision Medicine Market in Global (2022-2032)
  • Table 3: Artificial Intelligence (AI) in Precision Medicine Market in Global by Product (2022-2032)
  • Table 4: Artificial Intelligence (AI) in Precision Medicine Market in Global by Technology (2022-2032)
  • Table 5: Artificial Intelligence (AI) in Precision Medicine Market in Global by Application (2022-2032)
  • Table 6: Artificial Intelligence (AI) in Precision Medicine Market in Global by Therapeutic Area (2022-2032)
  • Table 7: Artificial Intelligence (AI) in Precision Medicine Market in Global by Geography (2022-2032)
  • Table 8: Artificial Intelligence (AI) in Precision Medicine Market in North America (2022-2032)
  • Table 9: Artificial Intelligence (AI) in Precision Medicine Market in the United States (2022-2032)
  • Table 10: Artificial Intelligence (AI) in Precision Medicine Market in Canada (2022-2032)
  • Table 11: Artificial Intelligence (AI) in Precision Medicine Market in Mexico (2022-2032)
  • Table 12: Artificial Intelligence (AI) in Precision Medicine Market in Europe (2022-2032)
  • Table 13: Artificial Intelligence (AI) in Precision Medicine Market in France (2022-2032)
  • Table 14: Artificial Intelligence (AI) in Precision Medicine Market in Germany (2022-2032)
  • Table 15: Artificial Intelligence (AI) in Precision Medicine Market in United Kingdom (2022-2032)
  • Table 16: Artificial Intelligence (AI) in Precision Medicine Market in Italy (2022-2032)
  • Table 17: Artificial Intelligence (AI) in Precision Medicine Market in Spain (2022-2032)
  • Table 18: Artificial Intelligence (AI) in Precision Medicine Market in the Rest of Europe (2022-2032)
  • Table 19: Artificial Intelligence (AI) in Precision Medicine Market in Asia-Pacific (2022-2032)
  • Table 20: Artificial Intelligence (AI) in Precision Medicine Market in China (2022-2032)
  • Table 21: Artificial Intelligence (AI) in Precision Medicine Market in Japan (2022-2032)
  • Table 22: Artificial Intelligence (AI) in Precision Medicine Market in India (2022-2032)
  • Table 23: Artificial Intelligence (AI) in Precision Medicine Market in Australia (2022-2032)
  • Table 24: Artificial Intelligence (AI) in Precision Medicine Market in South Korea (2022-2032)
  • Table 25: Artificial Intelligence (AI) in Precision Medicine Market in Rest of Asia-Pacific (2022-2032)
  • Table 26: Artificial Intelligence (AI) in Precision Medicine Market in the Rest of the World (2022-2032)
  • Table 27: Artificial Intelligence (AI) in Precision Medicine Market in the Middle East (2022-2032)
  • Table 28: Artificial Intelligence (AI) in Precision Medicine Market in Africa (2022-2032)
  • Table 29: Artificial Intelligence (AI) in Precision Medicine Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Artificial Intelligence (AI) in Precision Medicine Market in Global (2022-2032)
  • Figure 3: Artificial Intelligence (AI) in Precision Medicine Market in Global by Product (2022-2032)
  • Figure 4: Artificial Intelligence (AI) in Precision Medicine Market in Global by Technology (2022-2032)
  • Figure 5: Artificial Intelligence (AI) in Precision Medicine Market in Global by Application (2022-2032)
  • Figure 6: Artificial Intelligence (AI) in Precision Medicine Market in Global by Therapeutic Area (2022-2032)
  • Figure 7: Artificial Intelligence (AI) in Precision Medicine Market in Global by Geography (2022-2032)
  • Figure 8: Artificial Intelligence (AI) in Precision Medicine Market in North America (2022-2032)
  • Figure 9: Artificial Intelligence (AI) in Precision Medicine Market in the United States (2022-2032)
  • Figure 10: Artificial Intelligence (AI) in Precision Medicine Market in Canada (2022-2032)
  • Figure 11: Artificial Intelligence (AI) in Precision Medicine Market in Mexico (2022-2032)
  • Figure 12: Artificial Intelligence (AI) in Precision Medicine Market in Europe (2022-2032)
  • Figure 13: Artificial Intelligence (AI) in Precision Medicine Market in France (2022-2032)
  • Figure 14: Artificial Intelligence (AI) in Precision Medicine Market in Germany (2022-2032)
  • Figure 15: Artificial Intelligence (AI) in Precision Medicine Market in United Kingdom (2022-2032)
  • Figure 16: Artificial Intelligence (AI) in Precision Medicine Market in Italy (2022-2032)
  • Figure 17: Artificial Intelligence (AI) in Precision Medicine Market in Spain (2022-2032)
  • Figure 18: Artificial Intelligence (AI) in Precision Medicine Market in the Rest of Europe (2022-2032)
  • Figure 19: Artificial Intelligence (AI) in Precision Medicine Market in Asia-Pacific (2022-2032)
  • Figure 20: Artificial Intelligence (AI) in Precision Medicine Market in China (2022-2032)
  • Figure 21: Artificial Intelligence (AI) in Precision Medicine Market in Japan (2022-2032)
  • Figure 22: Artificial Intelligence (AI) in Precision Medicine Market in India (2022-2032)
  • Figure 23: Artificial Intelligence (AI) in Precision Medicine Market in Australia (2022-2032)
  • Figure 24: Artificial Intelligence (AI) in Precision Medicine Market in South Korea (2022-2032)
  • Figure 25: Artificial Intelligence (AI) in Precision Medicine Market in Rest of Asia-Pacific (2022-2032)
  • Figure 26: Artificial Intelligence (AI) in Precision Medicine Market in the Rest of the World (2022-2032)
  • Figure 27: Artificial Intelligence (AI) in Precision Medicine Market in the Middle East (2022-2032)
  • Figure 28: Artificial Intelligence (AI) in Precision Medicine Market in Africa (2022-2032)
  • Figure 29: Artificial Intelligence (AI) in Precision Medicine Market in South America (2022-2032)
  • Figure 30: Market Drivers
  • Figure 31: Market Barriers
  • Figure 32: Marker Opportunities
  • Figure 33: PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0865

Artificial Intelligence (AI) in Precision Medicine Market by Product (Hardware/Software and Services), Technology (Deep Learning, Natural Language Processing, and Machine Learning), Application (Drug Discovery & Development and Disease Diagnostics), Therapeutic Area (Oncology, Cardiology, Neurology, Infectious Disease, Immunology, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising cases of chronic & genetic diseases and growing product developmental activities worldwide

The Artificial Intelligence (AI) in precision medicine market was valued at USD 1,036.91 million in 2024, growing at a CAGR of 33.18% during the forecast period from 2025 to 2032 to reach USD 10,244.52 million by 2032. The Artificial Intelligence (AI) in Precision Medicine market is witnessing substantial growth, driven by the rising global prevalence of chronic and genetic diseases, which have amplified the demand for personalized treatment solutions. This momentum is further propelled by the increasing need for precision diagnostics and tailored therapeutics that leverage AI's capability to analyze complex biological data. Technological advancements in AI-powered platforms, combined with innovative product development, are enhancing the accuracy and speed of precision interventions. Additionally, a surge in research and development activities, alongside strategic product launches by key industry players, is accelerating market expansion. These converging factors are expected to significantly fuel the growth of the Artificial Intelligence (AI) in Precision Medicine market during the forecast period from 2025 to 2032.

Artificial Intelligence (AI) in Precision Medicine Market Dynamics:

According to GLOBOCAN data from 2023, approximately 20 million new cancer cases were reported in 2022, with this number projected to rise to 35 million by 2050 around the world.

As per the data from the World Health Organization (WHO) in 2024, in the WHO Eastern Mediterranean Region, over 788,000 cancer diagnoses were recorded in 2022. This figure is anticipated to double to approximately 1.57 million cases by 2045.

Data from the Breast Cancer Research Foundation (2024), reported that in 2022, about 2.3 million women were diagnosed with breast cancer worldwide. Also data from World Cancer Research Fund sated that (2024) there were about 2,480,675 cases of lung cancer and 1,926,425 cases of colorectal cancer were reported in 2022 across the globe.

The rising burden of cancer globally is significantly driving Artificial Intelligence (AI) in Precision Medicine market. As cancer care becomes more complex, there's an increasing need for advanced tools that can support early detection, accurate diagnosis, and personalized treatment strategies. AI-powered precision medicine solutions are gaining momentum for their ability to analyze vast datasets, uncover patterns, and guide tailored therapies, especially in oncology.

British Heart Foundation (2024), reported that approximately 640 million people worldwide were affected by heart and circulatory diseases in 2024, with around 67 million new diagnoses each year.

Further, International Diabetes Federation (2023), stated that 537 million adults aged between 20 and 79 were living with diabetes in 2021. This number expected to reach 643 million by 2030 and 783 million by 2045.

Additionally, WHO data indicated that, as of 2023, approximately 304 million people were living with viral infections like hepatitis B and C. In the same year, an estimated 39.9 million people were living with HIV, including 1.4 million children and 38.6 million adults.

The growing global burden of chronic and infectious diseases is significantly boosting the Artificial Intelligence (AI) in precision medicine market. As conditions like cardiovascular disease, diabetes, and chronic viral infections continue to rise, there is an increasing need for more targeted, efficient, and proactive treatment approaches. AI technologies are playing a crucial role by enabling earlier diagnosis, personalized treatment planning, and real-time patient monitoring. This shift toward data-driven, individualized care is driving demand for AI-integrated precision medicine solutions across healthcare systems worldwide.

The growing demand for personalized medicines and precision diagnostics is playing a significant role in driving the expansion of Artificial Intelligence (AI) in precision medicine market. According to data from the Personalized Medicine Coalition (2024), the U.S. FDA approved 16 new personalized treatments for rare disease patients in 2023, up from just six approvals in 2022. Among these, seven were cancer drugs, and three targeted other diseases and conditions, reflecting the increasing momentum in tailored therapeutic development.

The growing focus on individualized care is driving the integration of Artificial Intelligence (AI) into precision medicine, enabling a shift toward data-driven, patient-specific healthcare. AI algorithms analyze complex datasets, like genomics and health records to predict disease risks and guide personalized treatments. This includes identifying genetic mutations and tailoring interventions based on individual profiles.

Increasing research and development (R&D) activities and innovative product launches by leading industry players are significantly driving the growth of Artificial Intelligence (AI) in precision medicine market. For example, in June 2024, Tempus AI, Inc., a leader in artificial intelligence and precision medicine, announced it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-AF. This AI-powered tool helps identify patients who may be at an elevated risk of atrial fibrillation/flutter (AF), enabling earlier and more targeted interventions.

Hence, the interplay of the above-mentioned factors Artificial Intelligence (AI) precision market is poised to register significant growth during the forecast period from 2025 to 2032.

Despite its strong growth potential, Artificial Intelligence (AI) in precision medicine market is challenged by several key barriers. Concerns around data privacy and security, along with regulatory complexities and the need for thorough clinical validation, may limit market expansion during the forecast period.

Artificial Intelligence (AI) in Precision Medicine Market Segment Analysis:

Artificial Intelligence (AI) in Precision Medicine Market by Product (Hardware/Software and Services), Technology (Deep Learning, Natural Language Processing, and Machine Learning), Application (Drug Discovery & Development and Disease Diagnostics), Therapeutic Area (Oncology, Cardiology, Neurology, Infectious Disease, Immunology, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product segment of the Artificial Intelligence (AI) in precision medicine market, the hardware/software category is projected to hold the largest revenue share in 2024. This growth is largely driven by the rising cases of cancer globally and the numerous advantages offered by AI-powered software in both precision medicine and diagnostics.

For instance, according to GLOBOCAN 2024, there were 9,826,539 cancer cases reported in Asia, with this number projected to reach 16,336,291 by 2045. In North America, 2,673,174 cancer cases were recorded in 2022, projected to rise to 3,828,805 by 2045. Since, AI-powered platforms are increasingly relied upon for high-throughput data processing, imaging analysis, and predictive modeling, necessitating robust hardware infrastructure and sophisticated software solutions.

This surge in cancer cases is accelerating the adoption of AI technologies that support early detection, personalized treatment planning, and continuous disease monitoring, fueling market expansion across the precision medicine ecosystem.

AI-enabled precision medicine provides a wide range of advantages. AI algorithms can detect subtle patterns in medical imaging, genomic data, and clinical records, patterns that might be missed by human analysis. Also, AI-powered imaging tools can identify early-stage tumors and lesions with high sensitivity and specificity, enabling earlier diagnosis and intervention. Additionally, AI helps personalize therapies by analyzing a patient's unique genetic, molecular, and lifestyle profiles to predict treatment response, significantly reducing trial-and-error approaches in therapy selection.

AI models are also being used to determine which cancer patients that are most likely to benefit from immunotherapy based on their tumor genomics. Moreover, AI-driven software enables real-time analysis of treatment outcomes and patient responses, allowing clinicians to refine and optimize treatment plans dynamically. Tools powered by AI also assist pathologists in accurately identifying cancer types and grading tumors, enhancing consistency and diagnostic confidence across healthcare systems.

Several key players are actively contributing to market expansion through innovative AI software launches focused on precision medicine. For example, in March 2023, Qritive introduced QAi Prostate, an advanced AI tool specifically designed for prostate cancer diagnosis. Leveraging sophisticated machine learning algorithms, QAi Prostate analyzes whole slide images of prostate core needle biopsies with high precision. It identifies regions indicative of prostatic adenocarcinoma and classifies them into benign or malignant categories. This technology significantly improves diagnostic speed and accuracy, supporting more informed clinical decisions and improved patient outcomes.

Similarly, in November 2024, Aiforia and Paige announced a strategic partnership aimed at advancing Artificial Intelligence (AI) integration in pathology laboratories. Through this collaboration, both companies plan to jointly develop cutting-edge AI tools for precision diagnostics and scientific discovery, further accelerating the development and deployment of precision medicines.

Therefore, all the factors mentioned above are anticipated to witness robust growth in the product segment, thereby driving the overall expansion of Artificial Intelligence (AI) in precision medicine market during the forecast period from 2025 to 2032.

North America is expected to dominate the overall Artificial Intelligence (AI) in precision medicine market:

North America is expected to account for the largest share of Artificial Intelligence (AI) in precision medicine market during the forecast period 2025 to 2032. This dominance is driven by several key factors, including the rising instances of chronic disorder including cancer, lifestyle disease like diabetes, infectious diseases among others. Additionally, the strong R&D efforts focused on AI-based precision medicine, a well-established healthcare infrastructure, and continuous technological advancements in product development and regulatory approvals.

As per the data from GLOBOCAN (2024) revealed that the number of cancer cases in the U.S. reached 2,380,189 in 2022, with projections suggesting an increase to 2,791,752 cases by 2030. Similarly, Data from American Cancer Society in January 2025, 2,041,910 new cancer cases expected to be diagnosed in 2025 in the United States. Artificial Intelligence (AI) cancer precision medicine is emerging as a vital tool, aiming to optimize therapeutic outcomes and reduce treatment-related side effects by tailoring care to individual patients' genetic and clinical profiles.

According to the American Heart Association (2024), approximately 9.7 million adults were living with undiagnosed diabetes, while 29.3 million were diagnosed in the US. Furthermore, 115.9 million US population were reported to be dealing with pre-diabetes as of 2021. In precision medicine, AI plays an increasingly important role in diabetes care by enhancing diagnosis, predicting disease risk, and creating individualized treatment plans. By analyzing data from various sources, AI algorithms can detect patterns, forecast glucose fluctuations, and suggest personalized therapies, improving disease management.

Furthermore, data from the Centers for Disease Control and Prevention (2024) reported that in 2022, there were an estimated 31,800 new cases of HIV infection in the US. Hence, the continued emergence of complex health conditions, such as HIV, underscores the need for more precise, proactive, and individualized care strategies. This is driving the adoption of Artificial Intelligence (AI) in precision medicine, as it enables earlier detection, risk assessment, and personalized treatment planning. By leveraging patient data and predictive analytics, AI helps clinicians make more informed decisions and improve outcomes, especially for conditions that require lifelong management.

Moreover, leading industry players in the region are investing heavily in R&D to introduce advanced AI-based precision medicine tools. For example, in April 2024, Prenosis announced FDA De Novo marketing authorization for its Sepsis ImmunoScore(TM), an AI/machine learning software designed to guide precision diagnosis and risk prediction for sepsis.

Similarly, in February 2025, Ibex Medical Analytics received FDA 510(k) clearance for Ibex Prostate Detect, an in vitro diagnostic device that uses AI to generate heatmaps to identify small or rare prostatic cancers. This tool acts as a diagnostic safety net, helping pathologists deliver more accurate cancer diagnoses.

Thus due to interplay of aforementioned factors Artificial Intelligence (AI) in precision medicine is anticipated to register the significant growth in the North American region during the forecast period from 2025 to 2032.

Artificial Intelligence (AI) in Precision Medicine Market Key Players:

Some of the key market players operating in the Artificial Intelligence (AI) in precision medicine market include TEMPUS, GE HealthCare, Qure.ai, Envisionit Deep AI (Pty) Ltd., Avicenna.AI, Aignostics, Inc., Proscia Inc., Ultivue, Inc., Prenosis, Inc., IBEX, Cleerly, Inc., Paige AI, Inc., Densitas(R) Inc., Photocure ASA, iCAD, Inc., Eko Health, Inc., Owkin, Inc, Massive Bio, Deep Bio Inc., Atomwise Inc., and others.

Recent Developmental Activities in the Artificial Intelligence (AI) in Precision Medicine Market:

  • In April 2025, Illumina Inc. and Tempus AI, Inc. have partnered to accelerate the clinical adoption of next-generation sequencing tests. By combining Illumina's advanced AI technologies with Tempus's extensive multimodal data platform, the collaboration aims to train genomic algorithms and speed up the use of molecular testing in patient care.
  • In June 2024, Avicenna.AI, a leading medical imaging AI company, received 510(k) clearance from the US Food and Drug Administration (FDA) for CINA-VCF, an AI-powered triage and notification tool designed to detect unsuspected vertebral compression fractures (VCFs) in patients undergoing chest or abdomen CT scans.
  • In March 2024, Bayer and Aignostics have entered into a collaboration to advance next-generation precision oncology. Together, they will co-develop a novel target identification platform that utilizes multimodal patient data and cutting-edge AI/ML algorithms to enhance cancer treatment precision.
  • In June 2023, Illumina Inc., a global leader in DNA sequencing and array-based technologies, launched PrimateAI-3D, a cutting-edge AI algorithm capable of predicting disease-causing genetic mutations with unprecedented accuracy. This advancement enhances the ability to detect genetic risks earlier and contributes to more personalized treatment strategies

Key Takeaways from the Artificial Intelligence (AI) in Precision Medicine Market Report Study

  • Market size analysis for current Artificial Intelligence (AI) in precision medicine market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the Artificial Intelligence (AI) in precision medicine market.
  • Various opportunities available for the other competitors in the Artificial Intelligence (AI) in precision medicine market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current Artificial Intelligence (AI) in precision medicine market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for Artificial Intelligence (AI) in precision medicine market growth in the coming future?

Target Audience Who Can be benefited from this Artificial Intelligence (AI) in Precision Medicine Market Report Study

  • Artificial Intelligence (AI) in precision medicine product providers
  • Research organizations and consulting companies
  • Artificial Intelligence (AI) in precision medicine-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in Artificial Intelligence (AI) in precision medicine
  • Various end-users who want to know more about the Artificial Intelligence (AI) in precision medicine market and the latest technological developments in the Artificial Intelligence (AI) in precision medicine market.

Frequently Asked Questions for the Artificial Intelligence (AI) in Precision Medicine Market:

1. What are Artificial Intelligence (AI) in Precision Medicines?

  • Artificial Intelligence (AI) in precision medicine is the use of artificial intelligence to analyze health data and provide personalized diagnosis, treatment, and care based on an individual's unique genetic and clinical profile.

2. What is the market for Artificial Intelligence (AI) in precision medicines?

  • The Artificial Intelligence (AI) in precision medicine market was valued at USD 1,036.91 million in 2024, growing at a CAGR of 33.18% during the forecast period from 2025 to 2032 to reach USD 10,244.52 million by 2032.

3. What are the drivers for the global Artificial Intelligence (AI) in precision medicine market?

  • The Artificial Intelligence (AI) in Precision Medicine market is witnessing substantial growth, driven by the rising global prevalence of chronic and genetic diseases, which have amplified the demand for personalized treatment solutions. This momentum is further propelled by the increasing need for precision diagnostics and tailored therapeutics that leverage AI's capability to analyze complex biological data. Technological advancements in AI-powered platforms, combined with innovative product development, are enhancing the accuracy and speed of precision interventions. Additionally, a surge in research and development activities, alongside strategic product launches by key industry players, is accelerating market expansion. These converging factors are expected to significantly fuel the growth of the Artificial Intelligence (AI) in Precision Medicine market during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global Artificial Intelligence (AI) in precision medicine market?

  • Some of the key market players operating in the Artificial Intelligence (AI) in precision medicine market include TEMPUS, GE HealthCare, Qure.ai, Envisionit Deep AI (Pty) Ltd., Avicenna.AI, Aignostics, Inc., Proscia Inc., Ultivue, Inc., Prenosis, Inc., IBEX, Cleerly, Inc., Paige AI, Inc., Densitas(R) Inc., Photocure ASA, iCAD, Inc., Eko Health, Inc., Owkin, Inc, Massive Bio, Deep Bio Inc., Atomwise Inc., and others.

5. Which region has the highest share in the global Artificial Intelligence (AI) in precision medicine market?

  • North America is expected to account for the largest share of the Artificial Intelligence (AI) in precision medicine market in 2024. This dominance is driven by several key factors, including the rising instances of chronic disorder including cancer, lifestyle disease like diabetes, infectious diseases among others. Additionally, the strong R&D efforts focused on AI-based precision medicine, a well-established healthcare infrastructure, and continuous technological advancements in product development and regulatory approvals.

Table of Contents

1. Artificial Intelligence (AI) in Precision Medicine Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption
  • 1.4. Project Approach

2. Artificial Intelligence (AI) in Precision Medicine Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

5. Artificial Intelligence (AI) in Precision Medicine Market Key Factors Analysis

  • 5.1. Artificial Intelligence (AI) in Precision Medicine Market Drivers
    • 5.1.1. The rising cases of chronic & genetic diseases
    • 5.1.2. Increasing demand for personalized medicines and precision diagnostics
    • 5.1.3. Growing product developmental activities worldwide
  • 5.2. Artificial Intelligence (AI) in Precision Medicine Market Restraints and Challenges
    • 5.2.1. Data privacy and security concerns
    • 5.2.2. Regulatory hurdles and clinical validation issues
  • 5.3. Artificial Intelligence (AI) in Precision Medicine Market Opportunities
    • 5.3.1. Increasing role of predictive analytics in advancing Artificial Intelligence (AI) healthcare

6. Artificial Intelligence (AI) in Precision Medicine Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Artificial Intelligence (AI) in Precision Medicine Market Assessment

  • 7.1. By Product
    • 7.1.1. Hardware/Software
    • 7.1.2. Services
  • 7.2. By Technology
    • 7.2.1. Deep Learning
    • 7.2.2. Natural Language Processing
    • 7.2.3. Machine Learning
  • 7.3. By Application
    • 7.3.1. Drug Discovery & Development
    • 7.3.2. Disease Diagnostics
  • 7.4. By Therapeutic Area
    • 7.4.1. Oncology
    • 7.4.2. Cardiology
    • 7.4.3. Neurology
    • 7.4.4. Infectious Disease
    • 7.4.5. Immunology
    • 7.4.6. Others
  • 7.5. By Geography
    • 7.5.1. North America
      • 7.5.1.1. United States Artificial Intelligence (AI) in Precision Medicine Market Size in USD million (2022-2032)
      • 7.5.1.2. Canada Artificial Intelligence (AI) in Precision Medicine Market Size in USD million (2022-2032)
      • 7.5.1.3. Mexico Artificial Intelligence (AI) in Precision Medicine Market Size in USD million (2022-2032)
    • 7.5.2. Europe
      • 7.5.2.1. France Artificial Intelligence (AI) in Precision Medicine Market Size in USD million (2022-2032)
      • 7.5.2.2. Germany Artificial Intelligence (AI) in Precision Medicine Market Size in USD million (2022-2032)
      • 7.5.2.3. United Kingdom Artificial Intelligence (AI) in Precision Medicine Market Size in USD million (2022-2032)
      • 7.5.2.4. Italy Artificial Intelligence (AI) in Precision Medicine Market Size in USD million (2022-2032)
      • 7.5.2.5. Spain Artificial Intelligence (AI) in Precision Medicine Market Size in USD million (2022-2032)
      • 7.5.2.6. Rest of Europe Artificial Intelligence (AI) in Precision Medicine Market Size in USD million (2022-2032)
    • 7.5.3. Asia-Pacific
      • 7.5.3.1. China Artificial Intelligence (AI) in Precision Medicine Market Size in USD million (2022-2032)
      • 7.5.3.2. Japan Artificial Intelligence (AI) in Precision Medicine Market Size in USD million (2022-2032)
      • 7.5.3.3. India Artificial Intelligence (AI) in Precision Medicine Market Size in USD million (2022-2032)
      • 7.5.3.4. Australia Artificial Intelligence (AI) in Precision Medicine Market Size in USD million (2022-2032)
      • 7.5.3.5. South Korea Artificial Intelligence (AI) in Precision Medicine Market Size in USD million (2022-2032)
      • 7.5.3.6. Rest of Asia-Pacific Artificial Intelligence (AI) in Precision Medicine Market Size in USD million (2022-2032)
    • 7.5.4. Rest of the World (RoW)
      • 7.5.4.1. Middle East Artificial Intelligence (AI) in Precision Medicine Market Size in USD million (2022-2032)
      • 7.5.4.2. Africa Artificial Intelligence (AI) in Precision Medicine Market Size in USD million (2022-2032)
      • 7.5.4.3. South America Artificial Intelligence (AI) in Precision Medicine Market Size in USD million (2022-2032)

8. Artificial Intelligence (AI) in Precision Medicine Market Company and Product Profiles

  • 8.1. TEMPUS
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. GE HealthCare
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Qure.ai
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Envisionit Deep AI (Pty) Ltd.
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Avicenna.AI
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Aignostics, Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Proscia Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Ultivue, Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Prenosis, Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. IBEX
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Cleerly, Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Paige AI, Inc.
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Densitas(R) Inc.Co.
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Photocure ASACo.
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. iCAD, Inc.
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Eko Health, Inc.
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Owkin, Inc.
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Massive Bio
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Deep Bio Inc., Inc.
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Atomwise Inc.
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. About DelveInsight

11. Disclaimer & Contact Us